학술논문
Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes.
Document Type
Academic Journal
Author
Januszewski AS; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Level 6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, Sydney, NSW, 2050, Australia.; Chen D; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Level 6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, Sydney, NSW, 2050, Australia.; Monash School of Medicine, Monash University, Melbourne, VIC, Australia.; Scott RS; Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand.; O'Connell RL; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Level 6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, Sydney, NSW, 2050, Australia.; Aryal NR; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Level 6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, Sydney, NSW, 2050, Australia.; Sullivan DR; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Watts GF; Faculty of Health and Medical Sciences, School of Medicine, University of Western Australia, Perth, Australia.; Lipid Disorders Clinic, Cardiometabolic Services, Department of Cardiology, Royal Perth Hospital, Perth, Australia.; Taskinen MR; Cardiovascular Research Unit, Helsinki, Heart and Lung Centre, University Central Hospital, Helsinki, Finland.; Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland.; Barter PJ; Centre for Vascular Research, University of New South Wales, Sydney, NSW, Australia.; Faculty of Medicine, The University of Sydney, Sydney, NSW, Australia.; Best JD; Lee Kong Chian School of Medicine, Nanyang Technical University, Singapore, Singapore.; Simes RJ; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Level 6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, Sydney, NSW, 2050, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Keech AC; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Level 6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, Sydney, NSW, 2050, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Jenkins AJ; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Level 6 Medical Foundation Building, 92-94 Parramatta Rd, Camperdown, Sydney, NSW, 2050, Australia. alicia.jenkins@ctc.usyd.edu.au.; Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia. alicia.jenkins@ctc.usyd.edu.au.
Source
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
Subject
Language
English
Abstract
People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complications, and are altered by fenofibrate in adults with type 2 diabetes. Plasma LMW-F were quantified at baseline, after six weeks fenofibrate, and one year post-randomisation to fenofibrate or placebo. LMW-F associations with existing and new composite vascular complications were determined, and effects of fenofibrate assessed. LMW-F correlated positively with age, glycated haemoglobin (HbA1c), pulse pressure, kidney dysfunction and inflammation; and negatively with urate, body mass index, oxidative stress and leptin, albeit weakly (r = 0.04-0.16, all p < 0.01). Independent determinants of LMW-F included smoking, diastolic blood pressure, prior cardiovascular disease or microvascular complications, Caucasian ethnicity, kidney function, HbA1c and diabetes duration (all p ≤ 0.01). Baseline LMW-F tertiles correlated with on-trial macrovascular and microvascular complications (trend p < 0.001) on univariate analyses only. Six weeks of fenofibrate increased LMW-F levels by 21% (p < 0.001). In conclusion, LMW-F levels correlate with many risk factors and chronic diabetes complications, and are increased with fenofibrate. LMW-F tertiles predict complications, but not independently of traditional risk factors.
(© 2021. The Author(s).)
(© 2021. The Author(s).)